GU Cancers 2025 | MEVPRO-2: mevrometostat and enzalutamide in patients with ARPI-naïve mCRPC

Michael Schweizer • 14 Feb 2025

GU Cancers 2025

MEVPRO-2

Michael Schweizer, MD, Fred Hutchinson Cancer Center, Seattle, WA, gives an overview of the Phase III MEVPRO-2 trial (NCT06629779) of mevrometostat, an EZH2 inhibitor, with enzalutamide versus enzalutamide alone in androgen receptor pathway inhibitor (ARPI)-naïve metastatic castration-resistant prostate cancer (mCRPC). The primary endpoint is radiographic progression-free survival, with secondary endpoints including overall survival, pain progression, and safety. This interview took place at the ASCO GU Cancers Symposium 2025 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.